Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: Cross-sectional and longitudinal studies of event-related potentials

AIDS Research and Human Retroviruses

Volumn 18, Issue 7, 2002, Pages 485-490

  Husstedt, Ingo W ^a   Frohne, Lars ^a   Böckenholt, Sven ^a   Frese, Achim ^a   Rahmann, Alexandra ^a   Heese, Christoph ^a   Reichelt, Doris ^a   Evers, Stefan ^a  

^a University of M nich   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CELL COUNT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; EVENT RELATED POTENTIAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT PERIOD; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; REACTION TIME; SEROCONVERSION; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DIDANOSINE; DRUG THERAPY, COMBINATION; EVOKED POTENTIALS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; ZALCITABINE; ZIDOVUDINE;

EID: 0036252015     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202317406628     Document Type: Article

References (35)

1. The acquired immuno-deficiency syndrome (AIDS) dementia complex
2. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy
3. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: Support for the hypothesis of local virus replication
4. AIDS across Europe 1994-1998: The Euro SIDA study
5. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
6. HAART is neuroprophylactic in HIV-1 infection
7. Event-related potentials in human immunodeficiency virus infection
8. Longitudinal study of EEG and evoked potentials in neurologically asymptomatic HIV subjects
9. Electrophysiological study of neurologically asymptomatic HIV1 seropositive patients
10. Impact of antiretroviral treatment on AIDS dementia: A longitudinal prospective event-related potential study
11. Early detection of neurophysiological abnormalities in infection by human immunodeficiency virus
12. HIV-derived protein gp120 suppresses P3 potential in rats: Potential implications in HIV-associated dementia
13. Neuro-electric assessment of HIV: EEG, ERP, and viral load
14. The Edinburgh cohort of HIV positive drug users: Auditory event-related potentials show progressive slowing in patients with CDC stage IV disease
15. Event-related potentials in HIV-infected outpatients
16. Signs of cognitive change in HIV disease: An event-related brain potential study
17. HIV and the brain: Evidence of early involvement and progressive damage
18. Age-dependent decline in cognitive information processing of HIV positive individuals detected by event-related recordings
19. Auditory and visual event-related potentials in a controlled investigation of HIV-infection
20. Neurophysiological evaluation of zidovudine in asymptomatic HIV-1 infection: A longitudinal placebo-controlled study
21. Delayed latency of the event-related brain potential P3a component in HIV disease
22. Event-related potentials in HIV infection
23. Positive and sustained effects of highly active anti-retroviral therapy on HIV-1 associated neurocognitive impairment
24. 1993 Revised classification system for HIV infection
25. IFCN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee
26. Neurological outcome in late HIV-infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy
27. AIDS-dementia complex
28. Antiretroviral drugs and the central nervous system
29. The P300 wave of the human event-related potential
30. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia
31. Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
32. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir
33. Enhanced penetration of indinavir in cerebrospinal fluid and semen after addition of low-dose ritonavir
34. Antiretroviral therapy (ART) from a neurological point of view